This on-demand webinar describes an effective approach for studying PFAS in human whole blood and also discusses the challenges of PFAS analysis in blood serum and how to overcome them.
Historically, PFAS blood testing has been performed on the serum component of blood. Serum is a less complex matrix to work with compared to whole blood and many PFAS partition towards the serum.
The downside is that a blood draw and processing is required, which adds cost and complexity to an already expensive test.
The good news is that Eurofins has pioneered an approach that utilizes a field deployed, self-administered blood collection device paired with very sensitive instrumentation to achieve biologically relevant detection limits for PFAS.
- how to accelerate your study on the exposure of PFAS by studying PFAS in human whole blood
- about the challenges of PFAS analysis in blood serum and how to overcome them.
The Presenter
Andrew Patterson
Technical Director, Eurofins Environment Testing America - Specialty Services Division
Andrew brings 20 years of experience in the environmental laboratory industry with a focus on HRGC/HRMS analyses and also LC-MS/MS analyses. These approaches have focused on PCBs, dioxins, brominated flame-retardants, PFAS and emerging contaminants. Prior to Eurofins, Andrew was the Technical Director for Vista Analytical Laboratory in Northern California where he developed all aspects of PFAS capability within the lab. Before his time at Vista, Andrew worked in both the HRMS and LCMS laboratories at Alta Analytical with a focus on implementing performance-based EPA methods. Andrew holds a Bachelor’s of Science in Microbiology from Cal Poly San Luis Obispo, California, USA.
